Dr. Albert Bourla, chairman and CEO of drugmaker Pfizer, says mRNA technology is "extremely well-tested." - Dia Dipasupil/Getty Images Pharmaceutical rivals don’t often come to each other’s defense.

Filed in a Delaware federal court, the lawsuits claim the companies copied technology developed by Bayer's subsidiary, ...

Pfizer Inc.'s (NYSE:PFE) COVID-19 vaccine for children under five may lose U.S. Food and Drug Administration authorization this fall, raising the possibility of supply shortages and prompting Moderna ...

Last year, the High Court ruled that one of Moderna’s patents relating to the messenger RNA (mRNA) technology, which underpinned its COVID-19 vaccine, was valid and that Pfizer and BioNTech’s ...

Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published Wednesday in the New England Journal of Medicine. The vaccine uses the same ...

A little less than a year after targeting Moderna in an mRNA vaccine patent lawsuit, GSK is widening the scope of its litigation by throwing its rival’s next-generation COVID-19 shot into the fold. In ...

In a large-scale trial, modRNA was significantly better at preventing confirmed flu cases than a typical seasonal flu shot. Reading time 3 minutes Next-generation vaccines could make the flu season ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services terminated a contract with drugmaker Moderna to develop an mRNA bird flu ...